BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 37024146)

  • 1. Dopamine Receptor D1 Is Exempt from Transforming Growth Factor
    Gao AY; Diaz Espinosa AM; Nguyen BBN; Link PA; Meridew J; Jones DL; Gibbard DF; Tschumperlin DJ; Haak AJ
    J Pharmacol Exp Ther; 2023 Sep; 386(3):277-287. PubMed ID: 37024146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Antifibrotic Activity of Prostacyclin Receptor Agonism Is Mediated through Inhibition of YAP/TAZ.
    Zmajkovicova K; Menyhart K; Bauer Y; Studer R; Renault B; Schnoebelen M; Bolinger M; Nayler O; Gatfield J
    Am J Respir Cell Mol Biol; 2019 May; 60(5):578-591. PubMed ID: 30537446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autophagy and the unfolded protein response promote profibrotic effects of TGF-β
    Ghavami S; Yeganeh B; Zeki AA; Shojaei S; Kenyon NJ; Ott S; Samali A; Patterson J; Alizadeh J; Moghadam AR; Dixon IMC; Unruh H; Knight DA; Post M; Klonisch T; Halayko AJ
    Am J Physiol Lung Cell Mol Physiol; 2018 Mar; 314(3):L493-L504. PubMed ID: 29074489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P311 Promotes Lung Fibrosis via Stimulation of Transforming Growth Factor-β1, -β2, and -β3 Translation.
    Duan FF; Barron G; Meliton A; Mutlu GM; Dulin NO; Schuger L
    Am J Respir Cell Mol Biol; 2019 Feb; 60(2):221-231. PubMed ID: 30230348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TBK1 regulates YAP/TAZ and fibrogenic fibroblast activation.
    Aravamudhan A; Haak AJ; Choi KM; Meridew JA; Caporarello N; Jones DL; Tan Q; Ligresti G; Tschumperlin DJ
    Am J Physiol Lung Cell Mol Physiol; 2020 May; 318(5):L852-L863. PubMed ID: 32159970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compromised peroxisomes in idiopathic pulmonary fibrosis, a vicious cycle inducing a higher fibrotic response via TGF-β signaling.
    Oruqaj G; Karnati S; Vijayan V; Kotarkonda LK; Boateng E; Zhang W; Ruppert C; Günther A; Shi W; Baumgart-Vogt E
    Proc Natl Acad Sci U S A; 2015 Apr; 112(16):E2048-57. PubMed ID: 25848047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tubastatin ameliorates pulmonary fibrosis by targeting the TGFβ-PI3K-Akt pathway.
    Saito S; Zhuang Y; Shan B; Danchuk S; Luo F; Korfei M; Guenther A; Lasky JA
    PLoS One; 2017; 12(10):e0186615. PubMed ID: 29045477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Mechanisms for the Antifibrotic Action of Nintedanib.
    Rangarajan S; Kurundkar A; Kurundkar D; Bernard K; Sanders YY; Ding Q; Antony VB; Zhang J; Zmijewski J; Thannickal VJ
    Am J Respir Cell Mol Biol; 2016 Jan; 54(1):51-9. PubMed ID: 26072676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toll-like receptor 4 activation attenuates profibrotic response in control lung fibroblasts but not in fibroblasts from patients with IPF.
    Ebener S; Barnowski S; Wotzkow C; Marti TM; Lopez-Rodriguez E; Crestani B; Blank F; Schmid RA; Geiser T; Funke M
    Am J Physiol Lung Cell Mol Physiol; 2017 Jan; 312(1):L42-L55. PubMed ID: 27815256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Syndecan-2 exerts antifibrotic effects by promoting caveolin-1-mediated transforming growth factor-β receptor I internalization and inhibiting transforming growth factor-β1 signaling.
    Shi Y; Gochuico BR; Yu G; Tang X; Osorio JC; Fernandez IE; Risquez CF; Patel AS; Shi Y; Wathelet MG; Goodwin AJ; Haspel JA; Ryter SW; Billings EM; Kaminski N; Morse D; Rosas IO
    Am J Respir Crit Care Med; 2013 Oct; 188(7):831-41. PubMed ID: 23924348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GPCR-mediated YAP/TAZ inactivation in fibroblasts via EPAC1/2, RAP2C, and MAP4K7.
    Choi KM; Haak AJ; Diaz Espinosa AM; Cummins KA; Link PA; Aravamudhan A; Wood DK; Tschumperlin DJ
    J Cell Physiol; 2021 Nov; 236(11):7759-7774. PubMed ID: 34046891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SEMA3B inhibits TGFβ-induced extracellular matrix protein production and its reduced levels are associated with a decline in lung function in IPF.
    Yombo DJK; Ghandikota S; Vemulapalli CP; Singh P; Jegga AG; Hardie WD; Madala SK
    Am J Physiol Cell Physiol; 2024 Jun; 326(6):C1659-C1668. PubMed ID: 38646784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eliglustat exerts anti-fibrotic effects by activating SREBP2 in TGF-β1-treated myofibroblasts derived from patients with idiopathic pulmonary fibrosis.
    Kurumiya E; Iwata M; Kasuya Y; Tatsumi K; Honda T; Murayama T; Nakamura H
    Eur J Pharmacol; 2024 Mar; 966():176366. PubMed ID: 38296153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The small heat-shock protein αB-crystallin is essential for the nuclear localization of Smad4: impact on pulmonary fibrosis.
    Bellaye PS; Wettstein G; Burgy O; Besnard V; Joannes A; Colas J; Causse S; Marchal-Somme J; Fabre A; Crestani B; Kolb M; Gauldie J; Camus P; Garrido C; Bonniaud P
    J Pathol; 2014 Mar; 232(4):458-72. PubMed ID: 24307592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MARCH8 downregulation modulates profibrotic responses including myofibroblast differentiation.
    Guo X; Adeyanju O; Olajuyin AM; Mandlem V; Sunil C; Adewumi J; Huang S; Tucker TA; Idell S; Qian G
    Am J Physiol Cell Physiol; 2023 Nov; 325(5):C1190-C1200. PubMed ID: 37661917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective YAP/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosis.
    Haak AJ; Kostallari E; Sicard D; Ligresti G; Choi KM; Caporarello N; Jones DL; Tan Q; Meridew J; Diaz Espinosa AM; Aravamudhan A; Maiers JL; Britt RD; Roden AC; Pabelick CM; Prakash YS; Nouraie SM; Li X; Zhang Y; Kass DJ; Lagares D; Tager AM; Varelas X; Shah VH; Tschumperlin DJ
    Sci Transl Med; 2019 Oct; 11(516):. PubMed ID: 31666402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of Cellular Senescence Is Independent from Profibrotic Fibroblast-Deposited ECM.
    Blokland KEC; Habibie H; Borghuis T; Teitsma GJ; Schuliga M; Melgert BN; Knight DA; Brandsma CA; Pouwels SD; Burgess JK
    Cells; 2021 Jun; 10(7):. PubMed ID: 34209854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CCN5 overexpression inhibits profibrotic phenotypes via the PI3K/Akt signaling pathway in lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis and in an in vivo model of lung fibrosis.
    Zhang L; Li Y; Liang C; Yang W
    Int J Mol Med; 2014 Feb; 33(2):478-86. PubMed ID: 24276150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of Thy-1 results in TGF-β induced MMP-9 expression and confers a profibrotic phenotype to human lung fibroblasts.
    Ramírez G; Hagood JS; Sanders Y; Ramírez R; Becerril C; Segura L; Barrera L; Selman M; Pardo A
    Lab Invest; 2011 Aug; 91(8):1206-18. PubMed ID: 21577212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifibrotic effects of a novel pirfenidone derivative in vitro and in vivo.
    Ma Z; Zhao C; Chen Q; Yu C; Zhang H; Zhang Z; Huang W; Shen Z
    Pulm Pharmacol Ther; 2018 Dec; 53():100-106. PubMed ID: 30394340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.